Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
What is your approach to the use of immunosuppression for patients with poststreptococcal glomerulonephritis?
Related Questions
What are some measures to prevent flares of loin pain-hematuria syndrome?
Do you assess for podocyte detachment in addition to effacement when considering the degree of glomerular injury and potential treatment options following a native kidney biopsy in a patient with proteinuria?
What is your approach to immunosuppression in patients with preserved kidney function who are found to have nephrotic syndrome of unknown etiology and cannot safely undergo a kidney biopsy?
How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?
What is your treatment approach for patients with crescentic IgA nephropathy who fail to respond to cyclophosphamide and steroids?
What is your preferred initial therapy for patients with IgA nephropathy and more than 1 gram of proteinuria, given the recent approvals of sparsentan and budesonide alongside existing options like prednisone and ACEi/ARBs?
What are some indications that might lead you to pursue a kidney biopsy in a patient with presumed diabetic kidney disease?
What is your approach for steroid dosing for patients with ANCA vasculitis on induction treatment with rituximab, avacopan, and glucocorticoid therapy?
Do you prefer a mycophenolate or tacrolimus based glucocorticoid-sparing regimen for patients with minimal change disease?
Do you routinely obtain serum anti-THSD7A and anti-NELL1 tests in your patients with nephrotic syndrome suspected secondary to membraneous nephropathy?
